DMII
DMII
Drugs Made In America Acquisition II Corp. Ordinary SharesIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $155.51K ▲ | $-46.16K ▼ | 0% | $-0.02 ▼ | $-155.51K ▼ |
| Q2-2025 | $0 | $38.07K ▼ | $-38.07K ▲ | 0% | $0 ▲ | $-38.07K ▲ |
| Q1-2025 | $0 | $59.33K | $-59.33K | 0% | $-0 | $-59.33K |
What's going well?
The company earned $109,355 in interest income, which helped offset some of the losses. No debt or interest expense is a small positive.
What's concerning?
The company has no revenue, expenses are rising fast, and losses are getting worse. The big drop in share count is also unusual and could signal financial distress or a reverse split.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $315.09K ▲ | $501.01M ▲ | $18.18M ▲ | $482.83M ▲ |
| Q2-2025 | $4.39K ▼ | $113.39K ▲ | $327.51K ▲ | $-214.12K ▼ |
| Q1-2025 | $6.99K | $105.09K | $281.14K | $-176.05K |
What's financially strong about this company?
The company has no debt, a massive increase in assets and equity, and plenty of cash to cover all bills. Their asset base is high quality, with no risky goodwill or intangible assets.
What are the financial risks or weaknesses?
Retained earnings are still negative, showing a history of losses. Receivables have grown quickly, which could mean customers are paying slower. The big jump in equity likely came from issuing a huge number of new shares, which could dilute existing shareholders.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-46.16K | $-690.73K | $-500M | $501M | $310.69K | $-690.73K |
What's strong about this company's cash flow?
The company was able to raise a large amount of cash by issuing new shares, giving it some breathing room for now.
What are the cash flow concerns?
Operations are burning significant cash, and the company is highly dependent on selling new shares to keep going. Working capital is also draining cash, and there are no shareholder returns.
5-Year Trend Analysis
A comprehensive look at Drugs Made In America Acquisition II Corp. Ordinary Shares's financial evolution and strategic trajectory over the past five years.
DMII’s strengths today are structural and strategic rather than operational. It offers a public-company vehicle with access to capital, a focused thesis around domestic drug production, and a simple, transparent financial profile without complex operating items or intangible assets. The management team’s experience and industry relationships are central intangible strengths that, if leveraged well, could translate into a compelling acquisition.
Risks are substantial: there is no operating business, no revenue, negative equity, and weak liquidity supported by short-term debt. The company depends on external financing to cover ongoing costs and on successfully completing a merger within typical SPAC time constraints. Competition for attractive pharmaceutical and healthcare targets is intense, and regulatory and market conditions for SPACs have become more demanding, raising execution and timing risk.
The outlook is highly path-dependent and hinges on two things: DMII’s ability to stabilize its capital structure and its success in sourcing and closing a high-quality merger in its chosen niche. In the near term, financial pressure and reliance on short-term debt are important constraints. Over the longer term, if DMII secures a strong target aligned with domestic pharmaceutical resiliency, the combined company’s prospects will be driven far more by that acquired business’s economics and innovation than by the current shell’s standalone results.
About Drugs Made In America Acquisition II Corp. Ordinary Shares
https://dmaacorp.com/Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $155.51K ▲ | $-46.16K ▼ | 0% | $-0.02 ▼ | $-155.51K ▼ |
| Q2-2025 | $0 | $38.07K ▼ | $-38.07K ▲ | 0% | $0 ▲ | $-38.07K ▲ |
| Q1-2025 | $0 | $59.33K | $-59.33K | 0% | $-0 | $-59.33K |
What's going well?
The company earned $109,355 in interest income, which helped offset some of the losses. No debt or interest expense is a small positive.
What's concerning?
The company has no revenue, expenses are rising fast, and losses are getting worse. The big drop in share count is also unusual and could signal financial distress or a reverse split.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $315.09K ▲ | $501.01M ▲ | $18.18M ▲ | $482.83M ▲ |
| Q2-2025 | $4.39K ▼ | $113.39K ▲ | $327.51K ▲ | $-214.12K ▼ |
| Q1-2025 | $6.99K | $105.09K | $281.14K | $-176.05K |
What's financially strong about this company?
The company has no debt, a massive increase in assets and equity, and plenty of cash to cover all bills. Their asset base is high quality, with no risky goodwill or intangible assets.
What are the financial risks or weaknesses?
Retained earnings are still negative, showing a history of losses. Receivables have grown quickly, which could mean customers are paying slower. The big jump in equity likely came from issuing a huge number of new shares, which could dilute existing shareholders.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-46.16K | $-690.73K | $-500M | $501M | $310.69K | $-690.73K |
What's strong about this company's cash flow?
The company was able to raise a large amount of cash by issuing new shares, giving it some breathing room for now.
What are the cash flow concerns?
Operations are burning significant cash, and the company is highly dependent on selling new shares to keep going. Working capital is also draining cash, and there are no shareholder returns.
5-Year Trend Analysis
A comprehensive look at Drugs Made In America Acquisition II Corp. Ordinary Shares's financial evolution and strategic trajectory over the past five years.
DMII’s strengths today are structural and strategic rather than operational. It offers a public-company vehicle with access to capital, a focused thesis around domestic drug production, and a simple, transparent financial profile without complex operating items or intangible assets. The management team’s experience and industry relationships are central intangible strengths that, if leveraged well, could translate into a compelling acquisition.
Risks are substantial: there is no operating business, no revenue, negative equity, and weak liquidity supported by short-term debt. The company depends on external financing to cover ongoing costs and on successfully completing a merger within typical SPAC time constraints. Competition for attractive pharmaceutical and healthcare targets is intense, and regulatory and market conditions for SPACs have become more demanding, raising execution and timing risk.
The outlook is highly path-dependent and hinges on two things: DMII’s ability to stabilize its capital structure and its success in sourcing and closing a high-quality merger in its chosen niche. In the near term, financial pressure and reliance on short-term debt are important constraints. Over the longer term, if DMII secures a strong target aligned with domestic pharmaceutical resiliency, the combined company’s prospects will be driven far more by that acquired business’s economics and innovation than by the current shell’s standalone results.
CEO
Lynn Stockwell
Compensation Summary
(Year )
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
Summary
Showing Top 1 of 1